
    
      After providing informed consent, patients will undergo to a screening visit. If they meet
      the inclusion criteria and none of the exclusion will be included in this trial. Patients
      will take one tablet of Biktarvy at day for 48 weeks. Then the results will be compared with
      a cohort of 66 patiens treated with 2 nucleoside analogues and one integrase chain transfer
      inhibitor.
    
  